Modality
Radioligand
MOA
GLP-1/GIP
Target
TYK2
Pathway
Autophagy
T2DSchizophreniaPSP
Development Pipeline
Preclinical
Feb 2022
→ Jun 2031
PreclinicalCurrent
NCT08379359
2,410 pts·Schizophrenia
2022-02→2031-06·Recruiting
2,410 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-105.2y awayInterim· Schizophrenia
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2031-06-10 · 5.2y away
Schizophrenia
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08379359 | Preclinical | Schizophrenia | Recruiting | 2410 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| RAR-1117 | Ultragenyx | Phase 1/2 | TYK2 |